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Introduction
Peyronie’s Disease (PD) is manifested by the development 
of a fibrous inelastic scar within the tunica albuginea, which 
can lead to penile deformity, penile curvature, shrinkage, 
narrowing, hinging, shortening, and painful erections. 
These symptoms subsequently cause painful and/or 
unsatisfying sexual intercourse (1-7). 
Treatment options range from reassurance to medical, 
mechanical, and surgical options (1). Medical treatment 
options for PD are used to treat patients in the early/
acute phase of the disease. Although several reports in 
the literature exist of penile curvature stabilization and/or 
improvement in other clinical symptoms, recent guidelines 
describe that the available evidence reveals no significant 
benefit from common medical treatment options, especially 
for reducing penile curvature (3). On the other hand, 
according to the recent therapy guidelines, medical 
treatment options including either oral or intralesional 
injection therapy have been widely accepted as the standard 
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of care at the first presentation of men with PD (8). In 
addition to oral and intralesional injection therapy, several 
authors have also used other non-surgical treatment 
modalities to treat patients with PD, including topical 
therapy, extracorporeal shockwave therapy, iontophoresis, 
and penile traction therapy (PTT) (1-4). PTT, which 
produces gradual mechanical traction to the penis, has been 
described as an efficient, nonsurgical treatment option for 
men with PD. It has been suggested that application of 
PTT results in an enhancement in the length of the penis in 
both erect and flaccid forms (6,7).
In this article, we aim to review the current literature 
regarding the use of PTT in men with PD, and, additionally, 
its use in specific patient subgroups, including men with 
shortened penis prior to penile prosthesis placement.
Penile traction therapy (PTT) and Peyronie’s 
disease (PD):
Experimental data
Several studies have revealed that there are many similarities 
between PD and Dupuytren’s contracture (5,9). The most 
important finding was that several genes associated with 
collagen degradation, such as matrix metalloproteinases and 
those related to myofibroblast differentiation, were similar in 
both diseases, suggesting that the two conditions may share 
a common pathophysiological pathway (5,10). Therefore, 
investigators suggested that both conditions may potentially 
respond to similar therapeutic modalities (5). It has been 
previously shown that the use of mechanical traction and 
tissue expansion therapy leads to an alteration of connective 
tissue by cellular proliferation and expansion of the 
extracellular matrix (5). Tissue traction, or the use of tension 
to evoke a biologic response, has been investigated in 
numerous other clinical conditions and in several disciplines. 
The mechanism, namely “mechanotransduction”, has been 
described as a process that converts mechanical stimuli to 
cellular biochemical responses (5). Although the concept of 
‘tissue traction therapy’ had not been studied in the penis or 
PD models until the early 2000s, the biochemical response 
to tissue traction has previously been investigated in skin, 
bone, skeletal muscle and Dupuytren’s models (11-14). In 
Dupuytren’s contracture, a pro-fibrotic clinical condition 
similar to PD, continuous and prolonged mechanical 
tension on the fibrotic tissue may cause collagen remodeling 
and tendon healing (15). Additionally, histological staining 
studies have shown that, after traction therapy, there is 
reorganization and remodeling of collagen fibers into 
uniform, densely packed fibrils that are parallel to the 
axis of mechanical strain (16). Chung et al. performed 
the first experimental study related to the efficacy of 
tissue traction therapy in PD in a rigorously designed 
model (5). Briefly, using a cyclic strain culture system, the 
authors investigated the cellular changes to the tunical 
tissue following equibiaxial traction forces. The authors 
hypothesized that the observed protein alteration following 
mechanical traction should replicate the changes seen in 
tunical tissue following PTT. In this study, both qualitative 
[immunohistochemistry (IHC)] and quantitative (Western 
Blot assay) measurements were examined, hence increasing 
the value and reliability of the study. The results of this 
excellent study revealed that there was a significant increase 
in smooth muscle α-actin, β-catenin, and Hsp-47 protein 
contents measured in PD patients, as compared with the 
control group. Changes in IHC and Western immunoblot 
assays were seen after exposure to cellular equibiaxial 
tractional forces. IHC staining revealed a decrease in α-actin 
staining while Western Blot assay showed a prominent 
increase in metalloproteinase-8 expression with no measured 
change in β-catenin level in the stained PD group (5). 
This interesting study of cells obtained from PD and 
normal human tunica albuginea cultured in a mechanical 
strained environment provided important and promising 
evidence for the use of PTT in men with PD for plaque 
remodeling. Evidence obtained from these basic science 
experiments lends support to the clinical use of PTT. It is 
expected that PTT use in PD should yield similar outcomes 
as those seen with Dupuytren’s disease or any other similar 
clinical conditions. 
Clinical data
There are several commercially available penile stretching 
or traction devices for PD, including FastSize Penile 
Extender device (FastSize Medical, Aliso Viejo, CA, USA), 
Andro-Penis (Andromedical, Madrid, Spain), Golden 
Erect extender device (Ronas Tajhiz Teb, Tehran, Iran), 
SizeGenetics (GRT Net Services Inc., Gresham, OR, 
USA), Vimax Extender (OA Internet Services, Montreal, 
Canada) and ProExtender (Leading Edge Herbals, Greeley, 
CO, USA). These devices consist of parallel rods connected 
to two padded rings, one proximally at the base of the 
penis and a second distally underneath the corona. PTT 
is performed by holding the penis in a small frame and 
applying a gentle, but progressive, traction force on it, 
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which can be accomplished by the addition of small metal 
extensions to the parallel dynamic rods and frame for 
certain time periods (5,7). Available data related to PTT 
treatment is summarized in Table 1.
The first report for the use of PTT in men with PD 
was presented at the 4th annual meeting of the European 
Society for Sexual and Impotence Research (ESSIR) in 
2001. In this small study, eight men with at least a 3 months 
history of PD without ED underwent PTT for 4 h per day 
for a total of 3–6 months. The authors reported a 4.1-cm 
increase in mean penile length (P˂0.05) and a 14° decrease 
in mean erect penile deviation (from 34° to 20°; P˂0.05) in 
this series (17). 
Levine et al. evaluated the efficacy of prolonged external 
PTT as a nonsurgical treatment option in 10 men with PD. 
In this non-controlled pilot study of PTT, patients were 
treated using the FastSize penile extender. Traction was 
applied as the only treatment for 2–8 h per day for 6 months. 
Penile curvature, and stretched penile length and girth were 
measured before and after treatment. Additionally, erectile 
and sexual function was assessed using the International 
Index of Erectile Function-5 (IIEF-5) and Quality of 
Life Specific to Male Erection Difficulties (QOL-MED) 
questionnaires. At the end of the study, all men reported 
reduced curvature (10–40°), increased penile length 
(1–2.5 cm), and increased erect penile girth (0.5–1 cm), 
with correction of hinge effect in four out of four men. 
However, there was no significant change in quality of 
life by QOL-MED in this series. The authors of this pilot 
study concluded that, even though the study included small 
number of patients, early results suggested that prolonged 
daily use of PTT treatment should be considered as a new 
approach for the nonsurgical treatment of PD. Additionally, 
the authors noted the need for further well designed, 
randomized studies with larger numbers of patients (18). 
One year later, Gontero et al. (19) reported the results 
of PTT use in men with a minimum of 12 months history 
of PD and penile curvature of less than 50°. In this study, 
penile measurements were obtained by photographs taken 
by the researchers after a vasoactive agent induced an 
artificial erection. The patients were instructed to use the 
PTT for a minimum of 5 h per day, up to a maximum of 9 h. 
The results of this study showed that, in PD patients who 
completed the study, penile curvature decreased without 
Table 1 Clinical data published on PTT
Author Number of patients Patient group Duration of treatment Efficacy
Levine et al., 2008 10 PD patients 2–8 h/day; 6 months CI: 10°–40°; SPL: 0.5–2 cm
Gontero et al., 2008 15 ‘Short penis’ 4 h/day; 6 months FPL: 2.3 cm; SPL: 1.7 cm
Levine et al., 2011 10 ‘Short penis’ before IPP 2–4 h/day; 4 months SPL: 0.5–3 cm
Nikoobakht et al., 2011 23 ‘Short penis’ 4–6 h/day–2 weeks;  
9 h/day up to 3 months
FPL:1.7 cm; SPL: 1.7 cm
Rybak et al., 2012 TAP: 52; PTT(+): 27; 
PTT(−): 25; PEG: 59; 
PTT(+): 36; PTT(−): 23
PD patients after TAP or 
PEG surgery
>2 h/day; 3 months SPL; TAP (PTT+): 0.85 cm;  
TAP (PTT−): −0.53 cm;  
PEG (PTT+): 1.48 cm;  
PEG (PTT): 0.24 cm
Abern et al., 2012 IVI: 35; IVI+PTT: 39 PD patients after IVI 2–8 h/day; 6 months EPC (IVI): −20.9°;  
EPC (IVI+PTT): −26.9°;  
SPL (IVI): −0.74 cm;  
SPL (IVI+PTT): 0.6 cm
Martinez-Salamanca  
et al., 2014
PTT(+): 55; PTT(−): 41 Acute phase PD patients 6–9 h/day; 6 months EPC (PTT+): −20°;  
EPC (PTT−): +23°
Nowrozzi et al., 2015 54 Penile dysmorphophobia 4–6 h/day; 6 months SPL: 1.3 cm; FPL: 1.7 cm
Yafi et al., 2015 INF: 78; INF+PTT: 34 PD patients with previous 
INF α-2b treatment
Daily use of less or 
greater than 3 h
SPL (<3 h PTT): 1.3 cm;  
(>3 h PTT): 4.4 cm
PTT, penile traction therapy; PD, Peyronie’s disease; CI, curvature improvement; SPL, change in streched penile length; FPL, Change 
in Flaccid Penile Length; TAP, tunica albuginea plication; PEG, plaque excison and grafting; EPC, change in erect penile curvature; IVI, 
ıntralesional verapamil ınjection; INF, ınterferon α-2b.
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statistical significance (31° to 27°; P=0.056); however, 
there was a significant improvement in the mean flaccid 
and stretched penile length measurements (1.3 and 0.8 cm, 
respectively). More importantly, the authors reported 
that there was no further change in penile curvature or 
length even 6 months after PTT. The results of this study 
suggested that, although the use of a penile extender device 
provided minimal improvements in penile curvature, there 
was a reasonable level of patient satisfaction, most probably 
because of increased penile length.
Recently, in a nonrandomized prospective controlled 
trial, investigators specifically assessed the efficacy of a penile 
traction device for the treatment of men in the acute phase of 
PD. In this study, 55 patients underwent PTT for 6 months, 
and were compared with 41 patients with acute phase of 
PD who did not receive active therapy. The results of the 
study showed that penile curvature decreased from 33° at 
baseline to 15° at 6 months and 13° at 9 months with a mean 
decrease of 20° (P˂0.05) in the PTT group. Additionally, 
pain scores significantly decreased after 6 months 
while erectile function and erection hardness also improved 
significantly in the PTT group, compared to the no 
intervention group. Furthermore, PTT was associated with 
the disappearance of sonographic penile plaques in 48% 
of PD patients, and the need for surgery was eliminated in 
40% of patients who were, otherwise, good candidates for 
surgery. Altogether, these results suggested that PTT is an 
effective treatment option for the acute phase of PD, with 
significant decreases in pain and penile curvature, and an 
improvement in erectile function (6).
Abern et al. also described the use of PTT as a part 
of a combination treatment modality for men with PD. 
This study aimed to investigate the benefit of PTT when 
combined with intralesional verapamil injections and 
oral L-Arginine 1 g b.i.d. and pentoxifylline 400 mg t.i.d. 
in men with PD. Briefly, 74 men with PD completed 
12 intralesional verapamil injections. Patients who opted for 
PTT used the device for 2–8 h daily. Stretched penile length 
and erect penile curvature using penile ultrasonography 
were measured. A ≥10° improvement in penile curvature was 
considered a clinically significant response to therapy. Men 
who used the device more than 3 h per day gained 0.6 cm 
in stretched penile length vs. 0.07 cm when used less than 3 h 
per day, while men who did not use the device lost 0.74 cm 
of stretched penile length on average. In summary, this 
study showed that better curvature improvement and 
stretched penile length gain was seen in the combination 
group. Additionally, multivariate analysis revealed that 
length improvement was related to the duration of traction 
device use (20).
More recently, in a similar study by Yafi et al., the 
benefit and duration of daily PTT was assessed in men 
with PD who underwent interferon α-2b therapy. A total 
of 112 patients underwent a median of 12 interferon 
α-2b injections, with daily use of PTT reported by 31% 
of patients. The results of this study showed that the use 
of penile traction did not affect change in penile girth. 
However, men who used PTT 3 or more hours per 
day gained significantly greater stretched penile length 
compared to those who did not undergo PTT (21). 
The use of penile traction therapy (PTT) before 
penile surgery
Inflatable penile prosthesis (IPP) implantation is the 
standard of care for the treatment of patients with advanced 
ED, and/or is unresponsive to nonsurgical therapy. In most 
series, though the patient/partner satisfaction rates are 
generally high, concerns remain about penile length after 
IPP placement amongst a considerable group of patients. In 
a non-controlled pilot study, the effect of PTT in men with 
a shortened penis before IPP placement was investigated. 
This study included 10 patients who were instructed to 
wear the device for 2–4 h daily for 2–4 months before IPP 
placement. Baseline stretched penile length (SPL) was 
compared with post-traction SPL and post-implant inflated 
erect length. None of the patients complained about penile 
loss postoperatively, while 70% of men had measured 
length gain of up to 15 cm, compared with the baseline 
pre-traction SPL (22). 
Similarly, in men who underwent IPP placement 
after radical prostatectomy, and were dissatisfied with 
post-significant loss of penile length post-operatively, 
authors recommended PTT for 6 months before IPP 
revision surgery in order to increase penile length. After 
6 months of therapy, there was a 2.3-cm increase in SPL, 
which enabled the placement of a prosthesis that was 20% 
longer in length (15 to 18 cm), and erect penile length 
increased by 4.4 cm. These results suggested that the use of 
PTT increases penile corporal length, and, thus, the length 
of an IPP in a patient unsatisfied with his current IPP (23).
In another study conducted by Moncada-Iribarren et al., 
PTT was used in men who underwent PD surgery. In this 
series, 12 men had plaque incision + graft placement while 
28 underwent penile plication. Patients were randomized 
to PTT vs. observation. PTT was applied for 8–12 h per 
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day for at least 4 months. Penile shortening for both groups 
was from 0.5 to 4 cm. The use of PTT led to an increase in 
SPL, which ranged from 1 to 3 cm. Additionally, sustained 
treatment with PTT for 4 months caused an increase in 
SPL from 1 to 4 cm (24).
In a more recent study, authors have assessed patient 
outcomes with regards to SPL change and penile 
satisfaction after penile plication and partial plaque excision 
and grafting with or without postoperative application of 
PTT. The results of this study showed that, in patients who 
used PTT, there was no perceived length loss, while 58% 
reported a mean erect length gain of 1.1 cm, suggesting that 
postoperative PTT can result in length preservation, and, in 
most cases, measured and perceived length gain is possible 
after correction of the curvature (11).
Penile traction therapy (PTT) and penile 
dysmorphophobia
Penile dysmorphophobia has been defined as a body 
dysmorphic disorder. Body dysmorphia is a somatoform 
disorder conferred by preoccupation with an imaginary 
or trivial flaw in the physical appearance, which leads to 
deficiency in several areas of functioning. This problem can 
cause major depression and social dysfunction, which may 
ultimately lead to social isolation (25). Small penis syndrome 
has been described as an anxiety related to the external 
genitalia with the penile length being shorter than normal 
size for a normal adult (25). Studies have actually shown 
that, while there is an increase in men who are concerned 
about their penile length, most men complaining of short 
penis have, in fact, a normal sized penis (25,26). Real ‘Short 
penis-micropenis’ is defined as penile lengths of less than 
4 and 7.5 cm, respectively in the flaccid and stretched 
configurations (26). According to recent literature, the use 
of PTT in men with a ‘normal sized’ penis is suggested as 
an alternative option against several surgical interventions 
which actually may cause devastating results (27). 
In a phase-II prospective study conducted by Gontero, 
the efficacy of PTT was assessed in 15 men. After a 6-month 
treatment period, there was a significant gain in penile length 
(2.3 and 1.7 cm flaccid and stretched, respectively (28). 
In a similar study of 23 patients, PTT was applied for 4–6 h 
per day for the first 2 weeks and then 9 h per day until the 
end of the third month. Both flaccid and stretched penile 
sizes increased significantly during the first and second 
follow-up. Additionally, the circumference of the glans 
penis significantly increased after PTT (29). More recently, 
in another series, 54 men with a ‘short penis’ underwent 
PTT 4 to 6 h per day for 6 months. Flaccid, stretched, 
and erect penile length measurements were performed at 
baseline and again after 1, 3, 6 and 9 months. Additionally, 
erectile function was assessed at baseline and at 9 months 
after treatment by IIEF-5. A significant increase in flaccid, 
stretched, and erect penile length was observed at the 6th 
month follow-up, when compared to baseline values. On 
the other hand, no significant change was seen in penile 
girth after PTT treatment. Nine out of 13 patients with 
mild baseline ED reported normal erectile function after 
9 months of PTT (25).
Altogether, the results of these studies suggest that 
PTT should be considered as a noninvasive and effective 
treatment modality to increase penile length in patients 
seeking treatment for a ‘Short/small penis’. 
Conclusions
PTT is a relatively new area of interest for the nonsurgical 
treatment of men with PD. Additionally, PTT has been 
used in patients with postoperative loss of penile length, and 
for the management of men complaining of a small penis 
despite an objectively normal size. In the literature, there 
are an increased number of articles reporting promising 
results after the use of PTT. It is, however, important 
to consider several issues regarding PTT, including the 
efficacy of this therapy in the different subgroups of PD 
patients. Another important point is that, in comparison 
to PTT for the treatment of dysmorphophobia and 
postsurgical short penises, the lengthening benefit of this 
intervention in PD patients has been found to be inferior. 
Therefore, realistic expectations, especially in men with 
PD, should be discussed before recommending PTT. It 
should also be kept in mind that PTT requires a committed 
and compliant patient who is willing to devote time to a 
relatively long treatment period. Studies have shown that 
when used concomitantly with intralesional injection of 
both verapamil and INF α-2b, PTT provided a significant 
increase in stretched penile length when compared to no 
PTT. Therefore, it seems that PTT, in combination with 
intralesional plaque therapy, represents a good nonsurgical 
therapeutic option for men with PD. 
In conclusion, level 2b evidence (according to the 
Oxford Centre for Evidence-based Medicine) suggests 
that PTT is a tolerable, minimally invasive method for 
men with PD. However, most of the studies related to this 
treatment option are not well designed and have a limited 
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number of patients. Another important issue is that the 
time of device application (3 to 6 h) and treatment duration 
(3 to 6 months) remain to be defined. Further prospective, 
randomized, controlled studies with a larger number of 
patients and longer follow-up periods are needed. 
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